皮考布洛芬(Ibuprofen Piconol) - 药物靶点：COX-1 x COX-2_在研适应症：寻常痤疮，急性湿疹，慢性湿疹_专利_临床

概要

基本信息

药物类型

小分子化药

别名

Ibuprofen piconol (JP17/USAN)、イブプロフェンピコノール、ピメプロフェン

+ [6]

靶点

COX-1 x COX-2

作用机制

COX-1抑制剂(环氧化酶-1抑制剂)、COX-2抑制剂(环氧化酶-2抑制剂)

治疗领域

免疫系统疾病感染遗传病与畸形+ [1]

在研适应症

寻常痤疮急性湿疹慢性湿疹+ [5]

非在研适应症-

原研机构

Torii Pharmaceutical Co., Ltd.

在研机构

Hisamitsu Pharmaceutical Co., Inc.

Torii Pharmaceutical Co., Ltd.

非在研机构-

最高研发阶段批准上市

首次获批日期

日本 (1984-03-17),

急性湿疹慢性湿疹特应性皮炎+ [4]

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

结构

分子式C19H23NO2

InChIKeyACEWLPOYLGNNHV-UHFFFAOYSA-N

CAS号64622-45-3

关联

2

项与皮考布洛芬相关的临床试验

CTR20182200 / Not yet recruiting

布洛芬吡甲酯乳膏人体单中心、随机、开放、单剂量、平行设计的药代动力学比较研究

本试验为正式试验，旨在研究局部涂抹汕头经济特区鮀滨制药厂研制、生产的布洛芬吡甲酯乳膏（T：10 g﹕0.5 g）的药代动力学特征；以鳥居薬品株式会社生产的布洛芬吡甲酯乳膏（STADERM®，R：10 g﹕0.5 g）为参比制剂，评价受试制剂与参比制剂在布洛芬/布洛芬吡甲酯上的药动学参数（Cmax、AUC0-t、AUC0-∞）的差异性，并评价受试制剂的安全性。

开始日期-

申办/合作机构

山东百诺医药股份有限公司

CTR20182207 / Not yet recruiting

布洛芬吡甲酯软膏单中心、随机、开放、单剂量、平行试验设计人体药代动力学比较研究

本试验为正式试验，旨在研究局部涂抹汕头经济特区鮀滨制药厂研制、生产的布洛芬吡甲酯软膏（T：10 g﹕0.5 g）的药代动力学特征；以鳥居薬品株式会社生产的布洛芬吡甲酯软膏（STADERM®，R：10 g﹕0.5 g）为参比制剂，评价受试制剂与参比制剂在布洛芬/布洛芬吡甲酯上的药动学参数（Cmax、AUC0-t、AUC0-∞）的差异性，并评价受试制剂的安全性。

开始日期-

申办/合作机构

山东百诺医药股份有限公司

100 项与皮考布洛芬相关的临床结果

登录后查看更多信息

100 项与皮考布洛芬相关的转化医学

登录后查看更多信息

100 项与皮考布洛芬相关的专利（医药）

登录后查看更多信息

3

项与皮考布洛芬相关的文献（医药）

1996-01-01·Experimental Animals4区 · 医学

Spontaneous Comedones on the Skin of Hairless Descendants of Mexican Hairless Dogs.

4区 · 医学

Article

作者: DOI, Kunio ; KIMURA, Tohru

In the first experiment, the skin sebum and humidity, perspiration ability of sweat glands, and histology of spontaneous comedones were examined in hairless descendants of Mexican hairless dogs. The skin of females showed lower humidity than that of males. Some animals with a large number of comedones exhibited remarkably high skin sebum scores. The comedones were distributed throughout the dorsal skin, and a cluster of lesions was found mainly in the limbs and prepuces. The sweat glands showed no perspiration in the sudorific test. Histologically, both infant and adult animals had lesions of micro- and/or "blackhead" comedones. Plugged follicles containing abundant keratic substances associated well-developed sebaceous glands. Spontaneous comedones in the skin of hairless dogs were grossly and histologically similar to the acne vulgaris observed in human beings. The skin of some adult animals showed a large number of protrusive comedones which were solid cystic structures containing organized substances. In the second experiment, three kinds of antiacne agents (sulfur and camphor, sulfur and resorcinol, and ibuprofen piconol) were applied daily to the test sites for one month. These antiacne agents caused prominent extrusion of keratin plugs from follicular sites. The results suggest that the hairless dogs are a predictive model for evaluating the efficacy of antiacne agents proposed for acne treatment.

1991-01-01·Journal of Pharmaceutical Sciences3区 · 医学

Ibuprofen Piconol Hydrolysis In Vitro in Plasma, Whole Blood, and Serum Using Different Anticoagulants

3区 · 医学

Article

作者: Dennis Stalker ; J. Mark Christensen

Hydrolysis kinetics of ibuprofen piconol to ibuprofen were determined in vitro in plasma, whole blood, and serum. Varying initial concentrations of ibuprofen piconol with different anticoagulants (EDTA, heparin, citrate, or no anticoagulant) were used in determining the effects each had on the rate of ibuprofen piconol hydrolysis. Varying the initial concentration of ibuprofen piconol did not alter the hydrolysis half-life (concentration range from 50 to 200 micrograms/mL). The anticoagulant used altered the hydrolysis half-life. For plasma, the half-life was shortest when no anticoagulant was present (t 1/2 = 2.5 h) and longer with the presence of anticoagulants; for citrate, t 1/2 = 8.0 h, for heparin; t 1/2 = 15.5 h; and for EDTA, t 1/2 = 161.8 h. Red blood cell uptake of ibuprofen piconol was minimal and ranged from 0.4 to 4.1% over the ibuprofen piconol concentrations used in the study.

1988-03-01·Contact Dermatitis2区 · 医学

Contact dermatitis from ibuprofen piconol

2区 · 医学

Article

作者: Motoi Oguchi ; Tamiyo Akaeda ; Kinue Shirai ; Keiko Kubo

100 项与皮考布洛芬相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D01122	-	M02AA13 R02AX02 M01AE01 G02CC01 C01EB16	-

研发状态

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
寻常痤疮	日本	Torii Pharmaceutical Co., Ltd.	1986-02-13
急性湿疹	日本	Torii Pharmaceutical Co., Ltd.	1984-03-17
慢性湿疹	日本	Torii Pharmaceutical Co., Ltd.	1984-03-17
特应性皮炎	日本	Torii Pharmaceutical Co., Ltd.	1984-03-17
接触性皮炎	日本	Torii Pharmaceutical Co., Ltd.	1984-03-17
口周皮炎	日本	Torii Pharmaceutical Co., Ltd.	1984-03-17
带状疱疹	日本	Torii Pharmaceutical Co., Ltd.	1984-03-17
酒渣鼻样皮炎	日本	Torii Pharmaceutical Co., Ltd.	1984-03-17